Selective COX-2 Inhibitor Etoricoxib's Liposomal Formulation Attenuates M2 Polarization of TAMs and Enhances its Anti-metastatic Potential.

Usmani Mohammed AkifJaved MiyanRafquat Rananull MoinuddinNarayan Kumar Goswaminull TanzeelaSmrati BhadauriaManish Kumar Chourasia

Published in: Pharmaceutical research (2023)

As an epilogue, the developed formulation efficiently delivers poorly soluble etoricoxib, enhances its therapeutic potential as an anti-tumor and anti-metastatic agent, and directs explorative research for clinical translation.

Keyphrases

squamous cell carcinoma
small cell lung cancer
drug delivery
risk assessment
climate change